Cargando…
Chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Who really needs it
OBJECTIVES: The CSCO and ASCO guidelines in 2021 recommend chemotherapy for stage III–IVA (8th edition of AJCC staging) nasopharyngeal carcinoma (NPC). Actually, patients with stage T3–4N0M0 are often excluded from various clinical trials of the locoregionally advanced NPC, and the survival benefit...
Autores principales: | Qu, Weiling, Wang, Xuan, Qiao, Qiao, Wang, Yanli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067101/ https://www.ncbi.nlm.nih.gov/pubmed/36494918 http://dx.doi.org/10.1002/cam4.5497 |
Ejemplares similares
-
Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma
por: Li, Wen-Fei, et al.
Publicado: (2016) -
Prognostic Nomogram For Locoregionally Advanced Nasopharyngeal Carcinoma
por: Jiang, Yanming, et al.
Publicado: (2020) -
Is Gemcitabine and Cisplatin Induction Chemotherapy Superior in Locoregionally Advanced Nasopharyngeal Carcinoma?
por: Zheng, Wei, et al.
Publicado: (2015) -
Optimizing induction chemotherapy regimens for radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma
por: Li, Ying, et al.
Publicado: (2023) -
Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma()()()()
por: Jin, Ting, et al.
Publicado: (2019)